EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> MorphoSys obtained an option on Vivoryon Therapeutics’ small molecule QPCTL inhibitors in the treatment of cancer. The deal sees MorphoSys commit to take a €15 million ($17 million) stake in Vivoryon as part of an upcoming financing round. Statement

> Acacia Pharma detailed plans to refile for approval of Barhemsys in the third quarter. The disclosure of the plan follows a meeting with the FDA. Release  

> UniQure shared 36-week data on its hemophilia B gene therapy AMT-061. The mean FIX activity in the three patients treated with AMT-061 was 45% of normal. Statement 

> Freeline posted 12-month data on its hemophilia B gene therapy. FIX activity came in around 40%, but Freeline hopes to ramp that up to 50% to 150% once it optimizes the dose. Release 

> Vasopharm raised €9.5 million to fund work in support of a planned filing for approval of ronopterin. The German company is testing the allosteric iNOS inhibitor in traumatic brain injury patients. Statement 

> Redx Pharma sold a pan-RAF inhibitor to Jazz Pharmaceuticals for $3.5 million upfront. The deal for the preclinical oncology program includes $203 million in milestones. Release 

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .